Medera’s Sardocor announces fast track designation and dosing of 3 patients in first in human HFpEF gene therapy trial

14 February 2024 - In the Phase 1/2A clinical trial for SRD-001, an adeno-associated virus mediated first in human gene therapy ...

Read more →

Immuneering receives FDA fast track designation for IMM-1-104 in pancreatic cancer

20 February 2024 - Company expects multiple readouts from its Phase 1/2a clinical trial in 2024. ...

Read more →

PepGen receives US FDA fast track designation for PGN-EDODM1 for the treatment of myotonic dystrophy type 1

20 February 2024 - PepGen today announced that the US FDA has granted fast track designation to PGN-EDODM1, an investigational candidate ...

Read more →

Disc Medicine receives FDA fast track designation for DISC-0974 for the treatment of anaemia in non-dialysis dependent chronic kidney disease

20 February 2024 - Disc Medicine today announced that the US FDA has granted fast track designation to DISC-0974 for the ...

Read more →

Certa Therapeutics’ FT011 granted US FDA fast track for the treatment of systemic sclerosis

19 February 2024 - Certa Therapeutics today announces that the US FDA has granted fast track designation for its investigational therapy ...

Read more →

Caliway received US FDA fast track designation for CBL-514 for the treatment of Dercum's disease

14 February 2024 - CBL-514 is the first drug to receive fast track designation for Dercum's disease treatment. ...

Read more →

Diamyd Medical receives US FDA fast track designation for Diamyd

15 February 2024 - Diamyd Medical announced today that the US FDA has granted fast track designation for Diamyd (rhGAD65/alum) that ...

Read more →

CAN-3110 receives FDA fast track designation for treatment of recurrent high-grade glioma

13 February 2024 - Candel Therapeutics today announced that the US FDA granted fast track designation for CAN-3110 -- a first ...

Read more →

Edgewise receives US FDA fast track designation for EDG-5506 for the treatment of Duchenne muscular dystrophy

13 February 2024 - Edgewise Therapeutics today announced that the US FDA has granted fast track designation for EDG-5506 for the ...

Read more →

BioXcel Therapeutics receives FDA fast track designation for BXCL701 for treatment of small cell neuroendocrine prostate cancer

12 February 2024 - BXCL701 is an investigational, oral innate immune activator designed to inflame the tumour microenvironment and augment CPI ...

Read more →

GSK receives US FDA fast track designation for bepirovirsen in chronic hepatitis B

12 February 2024 - Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic ...

Read more →

Eplontersen granted US FDA fast track designation for patients with transthyretin-mediated amyloid cardiomyopathy

8 February 2024 - Ionis Pharmaceuticals announced today that the US FDA has granted fast track designation to Ionis and ...

Read more →

Arvinas and Pfizer’s vepdegestrant (ARV-471) receives FDA fast track designation for the treatment of patients with ER positive/HER2 negative metastatic breast cancer

6 February 2024 - Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the ...

Read more →

Ultimovacs receives FDA fast track designation for UV1 cancer vaccine for the treatment of patients with unresectable mesothelioma

5 February 2024 - The designation was granted by the US FDA based on results from the randomised Phase II clinical ...

Read more →

Biosyngen announces FDA fast track designation for BST02 in treatment of liver cancer

1 February 2024 - Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted fast track designation ...

Read more →